- Open Access
Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge
© Eugene et al.; licensee BioMed Central Ltd. 2013
- Received: 12 September 2012
- Accepted: 28 February 2013
- Published: 2 April 2013
The development of a preventative HIV/AIDS vaccine is challenging due to the diversity of viral genome sequences, especially in the viral envelope (Env160). Since it is not possible to directly match the vaccine strain to the vast number of circulating HIV-1 strains, it is necessary to develop an HIV-1 vaccine that can protect against a heterologous viral challenge. Previous studies from our group demonstrated that a mixture of wild type clade B Envgp160s were able to protect against a heterologous clade B challenge more effectively than a consensus clade B Envgp160 vaccine. In order to broaden the immune response to other clades of HIV, in this study rhesus macaques were vaccinated with a polyvalent mixture of purified HIV-1 trimerized consensus Envgp140 proteins representing clades A, B, C, and E. The elicited immune responses were compared to a single consensus Envgp140 representing all isolates in group M (Con M). Both vaccines elicited anti- Envgp140 IgG antibodies that bound an equal number of HIV-1 Envgp160 proteins representing clades A, B and C. In addition, both vaccines elicited antibodies that neutralized the HIV-1SF162 isolate. However, the vaccinated monkeys were not protected against SHIVSF162p4 challenge. These results indicate that consensus Envgp160 vaccines, administered as purified Envgp140 trimers, elicit antibodies that bind to Envgp160s from strains representing multiple clades of HIV-1, but these vaccines did not protect against heterologous SHIV challenge.
- Human Immunodeficiency Virus
- Rhesus Macaque
- Neutralize Antibody Titer
- Human Immunodeficiency Virus Protein
- Human Immunodeficiency Virus Vaccine
One of the greatest struggles for developing a preventative human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) vaccine is overcoming the diversity of viral isolates . The Envgp160 sequences can differ up to 35% between clades and ~15% within a specific clade . Viruses classified as clade B are responsible for ≥40% of infections in the Americas and Europe, but in Asia and sub-Saharan Africa, where most new infections are recorded each year, other clades are dominant. Most new infections in these regions are classified as clades A, C, or A/E viruses [1, 3]. Any HIV vaccine that will prevent infection must be able to overcome the diversity of HIV sequences.
To overcome the HIV sequence diversity, polyvalent mixture of antigens and consensus proteins were designed [4–7]. Polyvalent vaccines increase breadth by including multiple copies of a target (s) or epitopes into a single formulation. Polyvalent vaccine strategies have been employed to increase the breadth of the humoral and cellular immune responses [8, 9]. Polyvalent mixtures of Envgp140 or HIV proteins (Gag-Pol, Tat and trimeric Envgp140) elicit a degree of protection against heterologous challenge [8, 10]. Consensus-based vaccines rely on a centralized antigen designed to reduce sequence diversity by using the most common amino acid at each position of the protein. Consensus vaccines are designed to reduce the genetic differences between the vaccine and the primary isolate and increase the breadth of immune responses [11–14].
To overcome the diversity in Envgp160 sequences and to design a more effective AIDS vaccine, consensus Envgp140 sequences were designed for 4 clades of HIV-1 (A, B, C, and E), as well as a single consensus Envgp160 representing isolates from all of Group M. For the first time, in the same study, consensus A, B, C, and E Envgp140 sequences were used in a polyvalent vaccine mixture, and compared to a Con M Envgp160, to assess the ability to elicit a broadly reactive anti-Envgp160 immune response. The immunological responses of the polyvalent mixture in vaccinated rhesus macaques were compared to that of the single Con M Envgp140 vaccine. Both vaccines elicited anti-Env immune responses against multiple clades of HIV; however neither vaccine strategy efficiently protected monkeys against a SHIVSF162p4 challenge.
Characterization of consensus envelopes
The goal of this study was to design a HIV Envgp160 vaccine that elicits broadly reactive immune responses in an effort to overcome the inherent diversity in the Envgp160. Therefore, an HIV-1 group M consensus Envgp140 vaccine was compared to a polyvalent mixture of clade consensus Envgp140s representing 4 individual clades of HIV-1 (A, B, C, and E). The env gene sequences were then truncated at the transmembrane domain, and the cleavage site mutated, to generate a Envgp140. To stabilize the truncated Envgp140 trimers, the bacteriophage fibronectin domain (FT) was added to the 3’ end of the Envgp140 sequence, as previously described .
Vaccination of non-human primates with consensus envelopes
Vaccine groups and regimen of non-human primate study
Mixture of Con A,B,C,E Env gp140
Con M Env gp140
Depletion of CD8+ T cells
Information of envelopes used for assays
Mode of transmission
Length of infection
HIV env 6235 clone 3
PVO clone 4
pRHPA 4259 clone7
pTHRO4156 clone 18
Both Con M and polyvalent consensus Envgp140 vaccines elicited anti- Envgp140 antibodies that recognized Envgp160s from clade A, B and C. However, the Envgp160 SC42, THRO4, PVO4, (clade B), DU172 (clade C) and 93TH975 (clade E) were not significantly recognized by sera collected from vaccinated animals (Figure 2C). Overall, there was no binding preference of the elicited anti-Envgp160 antibodies to primary Envgp160s based on clade, location, or year of Envgp160 isolation.
Responses to the challenge envelope SF162
HIV-1 Envgp160 based vaccines protect monkeys against a homologous SHIV challenges [18, 19]. The ability to match the gene sequences used in the vaccine to the possible exposure virus in humans is not possible. Therefore, studies that use a matched Envgp160 in the vaccine to the challenge strain is appropriate for proof-of concept studies, but our group set a more challenging goal to protect against a challenge virus with a mismatched vaccine with a limited number of vaccinations. We report here that each consensus sequence representing clade A, B, C, E, in a polyvalent mixture or as a single consensus Envgp160 representing the entire Group M elicited anti-Envgp140 antibodies that bound to a broad panel of HIV-1 Envgp160s. The immunization schedule used was not optimal for antibody affinity maturation; nonetheless, the regimen did induce modest neutralizing antibody titers to the challenge Envgp160. However, the elicited immunity did not prevent infection by SHIVSF162p4.
In previous studies, consensus sequences designed for clades B and C Gag and Envgp140 elicited increased breadth of humoral and cellular immune responses [12, 20–22]. Consensus Envgp160 sequences representing Group M, termed CON-S, elicited antibodies that neutralized multiple Envgp160s, as well as eliciting cross-clade cellular immune responses [13, 14]. However, viral challenges of CON-S vaccinated monkeys were not reported and therefore the efficacy of the induced immune response elicited by these vaccines is unknown.
Compared to Envgp120 monomers, Envgp140 trimers may expose binding and neutralizing epitopes that are present only in Env’s quaternary state [23, 24]. Our consensus Envgp140 trimers have similar antigenic properties as wild-type Envgp160s, as demonstrated by attaching to human CD4 and binding to the monoclonal antibody b12. The b12 antibody recognizes a conserved region on gp120 mapped to a discontinuous epitope overlapping the CD4 binding site .
Following three intramuscular vaccinations, all monkeys seroconverted by day 14 following the final vaccination. Nonetheless, there were differences in the vaccine efficacy following challenge between the two vaccine groups. Both non-neutralizing and neutralizing antibodies have been implicated in reducing rates of infection by HIV-1 [26, 27]. A report based on the analysis of the sera samples of vaccinated volunteers in the RV144 clinical trial stated that the vaccine elicited antibodies against the V2 region of the HIV-1 Envgp160 were correlated with lower rates of HIV infection . Antisera collected from these vaccinated individuals did not neutralize the infection in vitro. Additionally, vaccine induced protection against a neutralization resistant virus in macaques was correlated with antibodies to the V2 region of Envgp160. Whether antibodies that bind to the V2 region are correlated with protection against SHIVSF162p4 infection in this study is unclear. There were no antibodies elicited in monkeys vaccinated with Con M or polyvalent consensus Envgp140 vaccines that recognized SF162 Envgp160 linear peptides, including those specific to V2 (data not shown). Further studies are necessary to determine if the two protected animals in the Con M Envgp140 group elicited antibodies recognizing conformational epitopes, such as the V1/V2 scaffold proteins. The V1/V2 scaffold was used to analyze human sera collected from vaccinated volunteers in the RV144 clinical trial [30, 31]. Determining if antibodies specific to various conformational epitopes on Envgp160 may explain the differences observed in vaccinated animals following SHIV challenge.
Two monkeys that had no detectable viral levels following SHIV infection were M1 and M4. M2 and M3 had detectable viral levels and therefore were not protected against infection. Monkeys vaccinated with either polyvalent consensus or Con M Envgp140 trimers had neutralizing titers to HIV-1SF162. Neutralizing antibodies against Envgp160 can protect monkeys against viral challenge [32, 33]. However, only one monkey (M4) in the present study had high neutralizing antibodies (1:320) against SHIVSF162p4 and had undetectable viral titer 14 days after challenge. However, following CD8+ T cell depletion, virus was detected (<1×105 RNA copies /ml) in the blood indicating that infection was not blocked, but may have been controlled by the vaccine elicited antibodies. T cell responses did not appear to play a role in protecting the monkeys from infection. There was no difference in the number or kinetics in the elicitation of Envgp160 or Gag specific IFNγ producing cells following challenge in any of the vaccinated monkeys compared to mock vaccinated animals.
Upon CD8+ depletion, it was not unexpected that M2 and M3 had a rebound in blood titer virus, but the detection M4 was unexpected. In contrast to monkey M4, no virus was detected in monkey M1 even after depletion of CD8+ T cells. Both IFNγ specific T cells and neutralizing antibodies were detected, but it is unclear which of these immune responses may have contributed to the protection. In addition, the MHC class I haplotype did not appear to correlate with protection. Even though no viremia was ever detected in monkey M1, it is possible that virus could be located in reservoirs, such as the bone marrow or gut mucosa . The M-T807R1 monoclonal antibody used for CD8+ T cell depletion is specific for cells in the serum and lymph nodes , therefore, it may have not depleted cells in reservoirs of hidden virus. In an effort to identify possible reasons for M1 protection the animals’ halotypes were determined. Monkey M1 had a Mamu-B*008 MHC class I haplotype, which has been associated with control of SIVmac239 virus; the parent virus of the challenge SHIVSF162p4. Therefore, a combination of the neutralizing antibodies, non-neutralizing antibodies and the Mamu-B*008 MHC class I haplotype may have resulted in “sterilizing” protection after viral challenge. However, the Mamu-B*008 MHC class I haplotype was also present in monkey M3, which had similar binding and neutralizing antibody titers as monkey M1, but was not protected from SHIV infection. Interestingly, two monkeys vaccinated with the polyvalent consensus vaccine, P2 and P4, had a rebound in viral titers at day 40 post-infection before returning to undetectable levels (Figure 3B). The rebound virus could have been a variant that escaped the vaccine elicited immune response, however, sequencing of the virus in the blood collected at day 40, did not show any significant variation of the viral sequence compared to the input virus on day 0.
While Envgp140 only vaccines have been successful against homologous challenge, both the human RV144 trial and previous monkey studies showed significant protection from heterologous challenge, included other HIV protein components [8, 37, 38]. Including Tat in the vaccine formulation induces strong and persistent CD4+ T cells  and broadens T cell responses directed against Gag and Envgp160[40, 41]. Gag is known for inducing strong cellular responses that may lead to reduced viral loads [42, 43]. Addition of Gag and/or Tat to our Con M vaccine may have prevented infection or controlled undetectable virus in vaccinated animals more effectively than Con M Envgp140 alone. Even though some of these studies use Envgp140 proteins, they are combined with other HIV proteins to elicit a broadly reactive response. In our vaccine presented here, the purified VLPs only have Gag and Envgp140 expressed in different modalities than VLPs and we achieve a broadly reactive anti-Envgp140 response using our consensus Envgp160s. For example, viral vectors are used to express Gag and Envgp160 independently in the RV144 human trial, which really does not allow for comparison with our VLP strategy.
Rhesus macaques were vaccinated with trimerized Envgp140 proteins representing consensus sequences for clade A, B, C, E, in a polyvalent mixture or as a single consensus Envgp160 representing the entire Group M. These consensus Envgp140 elicited antibodies with cross-clade anti-Envgp140 binding against a panel of HIV-1 Envgp160s. However, this breadth of antibody binding to HIV-1 Envgp160s only partially correlated with the prevention of infection by SHIVSF162p4.
The consensus sequences represent the most common amino acids found at each position of the aligned envelope sequences used. One hundred Envgp160s sequences per clade were used to design consensus sequences of clades A, B, C, and E. The design of the group M consensus Envgp160 was based on two hundred Envgp160 sequences representing clades A, B, C, D, E, F and H. Envgp160s chosen were isolated following mucosal transmission, within weeks after infection and included a diversity of viruses that were isolated in different locations around the world between 1995 and 2005. Each Envgp160 used the CCR5 co-receptor. Vaccine immunogens were designed as Envgp140 trimers as previously described .
Human embryonic kidney (HEK) 293T cells were transiently transfected with DNA (8 μg) expressing one of the consensus HIV-1 Envgp140 proteins or wild type Envgp120 6X-HIS tagged proteins. Following DNA transfection as previously described , secreted Envgp140 proteins were purified using lectin columns made from agarose galanthus nivalis (snowdrop) lectin (Vector laboratories, Burlingame, CA, USA)  and the Envgp120 6X-HIS tagged proteins were purified using nickel columns . Other purified Envgp160s used for ELISAs were purchased from eEnzyme (Gaithersburg, MD, USA). Each purified consensus Envgp140 trimer protein (1 μg) was loaded on to NativePAGE native gel (Invitrogen, Carlsbad, CA, USA) and separated by electrophoresis in the manufacture’s recommended buffers. After separation, the proteins were detected using the ProteoSilver Sliver Stain kit (Sigma, St. Louis, MO, USA) following manufacturer’s protocol .
CD4 binding assay
The CD4 binding assay was performed to demonstrate Envgp160 binding to its primary receptor using a similar protocol as previously described . Protein G Dynabeads (Invitrogen) were mixed with anti-his antibody. The tubes with the mixture were placed on the magnets to remove all unbound antibody. Then soluble human CD4-6XHIS tagged protein (eEnzyme, Gaithersburg, MD, USA) and consensus Envgp140 mixtures were then mixed with the beads. Following pellet fractionation, samples were separated on a 10% SDS PAGE gel, transferred unto a nitrocellulose membrane and probed for sCD4 or Envgp160 using specific antibodies. Following secondary IgG-HRP antibodies which were used to detect proteins by Western blot.
Surface plasmon resonance
MAb b12 binding kinetic analyses of the HIV rgp140(s) was performed by surface plasmon resonance (SPR) on a Biacore 3000 (GE/Biacore AB, Inc., Uppsala, Sweden) as previously described .
Animals and vaccination
Animals were treated according to the guidelines of the IACUC of the University of Pittsburgh. All the protocols used were approved by the IACUC of the University of Pittsburgh (#1002617). Rhesus macaques (Macaca mulatta) were used for all non-human primate experiments. All animals were cared for adhering to USDA guidelines for laboratory animals. Rhesus macaques were anesthetized using 10-20 mg/kg ketamine and vaccinated intramuscularly in the quadriceps and formulated with Imject® alum adjuvant (Imject® Alum, Pierce Biotechnology; Rockford, IL, USA). Vaccinations were completed at weeks 0, 4 and 8. Twelve animals were divided into three (3) groups, four animals per group (Table 1). For blood sample collection animals were anesthetized with a mixture of ketamine/xylazine. Sera was then harvested and stored at -80°C until needed.
Total anti-Envgp160 IgG was detected by enzyme-linked immunosorbent assay (ELISA) using Concanavalin A (50 μg/μl) per well as previously described . End point titer for assay was determined as the reciprocal of the dilution at which the optical density reading was above the mean plus two standard deviations of naïve sera. For In vitro neutralization, antisera were tested for the ability to neutralize virus infection in vitro using TZM-Bl indicator cells . The sera dilution necessary to neutralize virus was calculated by the following formula (relative light units (RLU) of virus only-RLU of cell only)/2 + RLU cell only. For assessment of T cell responses, NHP IFN-γ ELISPOT was used to enumerate anti-Envgp160 specific cellular responses. The number of anti-Envgp160 (SF162p3 and Con M) and Gag (SIVmac239) specific IFN-γ secreting cells were determined using the non-human primate enzyme-linked immunospot (ELISPOT) assay (R&D Systems, Minneapolis, MN, USA).
SHIV viral load determination
Real time PCR-based SIV viral detection assay was used to determine the viral titers post-challenge as described in . cDNA (10 μl) generated by the RT-RCR reaction was then used for PCR using the ABI 7000 Gene detection system (Applied Bioscience, Carlsbad, California, USA).
Anti-CD8 cell depletion by antibody administration
All animals in the Con M group were depleted of CD8+ T cells. The antibody M-T807R1 (NIH NHP Reagent Source, Beth Israel Deacones Medical Center, Boston, MA, USA) was administered subcutaneously (50 mg/Kg) on day 0 (Day 70 post infection). CD8+ T cell depletion was verified using TruCOUNT tubes (BD Bioscience, San Jose, CA, USA).
Statistical tests were performed using Graph Pad Prism software. Statistical significance of antibody test was determined by two-way analysis of variance (ANOVA) followed by the Bonferroni’s post-hoc test. Post-test was used to analyze differences between the vaccine groups. Significance was determined to be a p<0.05.
This research was primarily supported by an award from the National Institute of Health/National Institute of Allergy and Infectious Diseases R01AI068507 to T.M.R. The HIV and SIV specific peptides and reagents were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH including TZM-bl cells (also called JC57BL-13) (#8129). The authors would also thank investigators that provided specific HIV-1 isolates (Rob Center, Dennis Ellenberger, Phalguni Gupta, Beatrice Hahn, David Montefiori, Gary Nabel, Yiming Shao, and Carolyn Williamson). We are also grateful to Amara Luckay and Jim Smith at the CDC for determination of viral loads. This work was supported, in part, under a grant with the Pennsylvania Department of Health. The department specifically disclaims responsibility for any analyses, interpretations or conclusions.
- Hemelaar J: The origin and diversity of the HIV-1 pandemic. Trends Mol Med 2012,18(3):182-192. 10.1016/j.molmed.2011.12.001PubMedView ArticleGoogle Scholar
- Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V, Haynes B, Hahn BH, Bhattacharya T: Diversity Considerations in HIV-1 Vaccine Selection. Science (New York, NY) 2002, 296: 2354-2360. 10.1126/science.1070441View ArticleGoogle Scholar
- Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG: Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 2003,51(2):229-240. 10.1093/jac/dkg079PubMedView ArticleGoogle Scholar
- McBurney SP, Ross TM: Viral sequence diversity: challenges for AIDS vaccine designs. Expert Rev Vaccines 2008,7(9):1405-1417. 10.1586/14760522.214.171.1245PubMedPubMed CentralView ArticleGoogle Scholar
- Lu S, Grimes Serrano JM, Wang S: Polyvalent AIDS Vaccines. Curr HIV Res 2010,8(8):622-629. 10.2174/157016210794088290PubMedPubMed CentralView ArticleGoogle Scholar
- Arenas M, Posada D: Computational Design of Centralized HIV-1 Genes. Curr HIV Res 2010,8(8):613-621. 10.2174/157016210794088263PubMedView ArticleGoogle Scholar
- Gao F, Liao H-X, Hahn BH, Letvin NL, Korber BT, Haynes BF: Centralized HIV-1 Envelope Immunogens and Neutralizing Antibodies. Curr HIV Res 2007,5(6):572-577. 10.2174/157016207782418498PubMedView ArticleGoogle Scholar
- McBurney SP LG, Forthal DN, Ross TM: Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent clade B virus-like particle vaccine. AIDS Res Hum Retroviruses 2012. in PressGoogle Scholar
- Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA: Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA primeâ€“protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008,26(8):1098-1110. 10.1016/j.vaccine.2007.12.024PubMedPubMed CentralView ArticleGoogle Scholar
- Lakhashe SK, Wang W, Siddappa NB, Hemashettar G, Polacino P, Hu SL, Villinger F, Else JG, Novembre FJ, Yoon JK: Vaccination against Heterologous R5 Clade C SHIV: Prevention of Infection and Correlates of Protection. PLoS One 2011,6(7):e22010. 10.1371/journal.pone.0022010PubMedPubMed CentralView ArticleGoogle Scholar
- Yan J, Yoon H, Kumar S, Ramanathan MP, Corbitt N, Kutzler M, Dai A, Boyer JD, Weiner DB: Enhanced Cellular Immune Responses Elicited by an Engineered HIV-1 Subtype B Consensus-based Envelope DNA Vaccine. Mol Ther 2007,15(2):411-421. 10.1038/sj.mt.6300036PubMedView ArticleGoogle Scholar
- McBurney SP, Ross TM: Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 2009,27(32):4337-4349. 10.1016/j.vaccine.2009.04.032PubMedView ArticleGoogle Scholar
- Santra S, Korber BT, Muldoon M, Barouch DH, Nabel GJ, Gao F, Hahn BH, Haynes BF, Letvin NL: A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. PNAS 2008,105(30):10489-10494. 10.1073/pnas.0803352105PubMedPubMed CentralView ArticleGoogle Scholar
- Liao H-X, Sutherland LL, Xia S-M, Brock ME, Scearce RM, Vanleeuwen S, Alam SM, McAdams M, Weaver EA, Camacho ZT: A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006,353(2):268-282. 10.1016/j.virol.2006.04.043PubMedPubMed CentralView ArticleGoogle Scholar
- Bower JF, Li Y, Wyatt R, Ross TM: HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies. Vaccine 2006,24(26):5442-5451. 10.1016/j.vaccine.2006.03.063PubMedView ArticleGoogle Scholar
- Pantophlet R, Wilson IA, Burton DR: Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. PEDS 2004,17(10):749-758.PubMedGoogle Scholar
- Watkins JD, Siddappa NB, Lakhashe SK, Humbert M, Sholukh A, Hemashettar G, Wong YL, Yoon JK, Wang W, Novembre FJ: An Anti-HIV-1 V3 Loop Antibody Fully Protects Cross-Clade and Elicits T-Cell Immunity in Macaques Mucosally Challenged with an R5 Clade C SHIV. PLoS One 2011,6(3):e18207. 10.1371/journal.pone.0018207PubMedPubMed CentralView ArticleGoogle Scholar
- Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D: Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008,22(3):339-348. 10.1097/QAD.0b013e3282f3ca57PubMedView ArticleGoogle Scholar
- Barnett SW, Burke B, Sun Y, Kan E, Legg H, Lian Y, Bost K, Zhou F, Goodsell A, zur Megede J: Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant. J Virol 2010,84(12):5975-5985. 10.1128/JVI.02533-09PubMedPubMed CentralView ArticleGoogle Scholar
- Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Salazar-Gonzalez JF, Moldoveanu Z: Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 2007,360(1):218-234. 10.1016/j.virol.2006.10.017PubMedPubMed CentralView ArticleGoogle Scholar
- Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Weng Z, Weaver EA, Gao F: Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006,352(2):438-449. 10.1016/j.virol.2006.05.011PubMedView ArticleGoogle Scholar
- Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G: Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012. advance online publicationGoogle Scholar
- Sharma VA, Kan E, Sun Y, Lian Y, Cisto J, Frasca V, Hilt S, Stamatatos L, Donnelly JJ, Ulmer JB: Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines. Virology 2006,352(1):131-144. 10.1016/j.virol.2006.04.030PubMedView ArticleGoogle Scholar
- Harris A, Borgnia MJ, Shi D, Bartesaghi A, He H, Pejchal R, Kang Y, Depetris R, Marozsan AJ, Sanders RW: Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A 2011, 108: 11440-11445. 10.1073/pnas.1101414108PubMedPubMed CentralView ArticleGoogle Scholar
- Saphire EO, Parren PWHI, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA: Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design. Science 2001,293(5532):1155-1159. 10.1126/science.1061692PubMedView ArticleGoogle Scholar
- Holl V, Peressin M, Moog C: Antibody-Mediated Fcψ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies. Viruses 2009, 1: 1265-1294. 10.3390/v1031265PubMedPubMed CentralView ArticleGoogle Scholar
- Burton DR: Antibodies, viruses and vaccines. Nat Rev Immunol 2002,2(9):706-713. 10.1038/nri891PubMedView ArticleGoogle Scholar
- Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012,366(14)):1275-86.PubMedPubMed CentralView ArticleGoogle Scholar
- Barouch DH, Liu J, Li H, Maxfield LF, Abbink P, Lynch DM, Iampietro MJ, SanMiguel A, Seaman MS, Ferrari G: Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature advance online publicationGoogle Scholar
- Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E: Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Eng J Med 2009, 361: 2209-2220. 10.1056/NEJMoa0908492View ArticleGoogle Scholar
- Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R: Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. N Eng J Med 2012,366(14):1275-1286. 10.1056/NEJMoa1113425View ArticleGoogle Scholar
- Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI: Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIVBa-L. J Virol 2009, 84: 1302-1313.PubMedPubMed CentralView ArticleGoogle Scholar
- Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D: Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 2008,22(3):339-348. 10.1097/QAD.0b013e3282f3ca57PubMedView ArticleGoogle Scholar
- Smith M, Wightman F, Lewin S: HIV Reservoirs and strategies for eradication. Curr HIV/AIDS Rep 2012, 9: 5-15. 10.1007/s11904-011-0108-2PubMedView ArticleGoogle Scholar
- Veazey RS, Acierno PM, McEvers KJ, Baumeister SHC, Foster GJ, Rett MD, Newberg MH, Kuroda MJ, Williams K, Kim E-Y: Increased Loss of CCR5+ CD45RAâˆ’ CD4+ T Cells in CD8+ Lymphocyte-Depleted Simian Immunodeficiency Virus-Infected Rhesus Monkeys. J Virol 2008, 82: 5618-5630. 10.1128/JVI.02748-07PubMedPubMed CentralView ArticleGoogle Scholar
- Loffredo JT, Maxwell J, Qi Y, Glidden CE, Borchardt GJ, Soma T, Bean AT, Beal DR, Wilson NA, Rehrauer WM: Mamu-B*08-Positive Macaques Control Simian Immunodeficiency Virus Replication. J Virol 2007, 81: 8827-8832. 10.1128/JVI.00895-07PubMedPubMed CentralView ArticleGoogle Scholar
- Lakhashe SK, Velu V, Siddappa NB, Dipasquale JM, Hemashettar G, Yoon JK, Rasmussen RA, Yang F, Lee SJ, Montefiori DC: Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine 2011,29(34):5611-24. 10.1016/j.vaccine.2011.06.017PubMedPubMed CentralView ArticleGoogle Scholar
- Sundling C, Forsell MN, O'Dell S, Feng Y, Chakrabarti B, Rao SS, Loré K, Mascola JR, Wyatt RT, Douagi I: Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med 2010,207(9):2003-2017. 10.1084/jem.20100025PubMedPubMed CentralView ArticleGoogle Scholar
- Leroux-Roels I, Koutsoukos M, Clement F, Steyaert S, Janssens M, Bourguignon P, Cohen K, Altfeld M, Vandepapelière P, Pedneault L: Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 2010,28(43):7016-7024. 10.1016/j.vaccine.2010.08.035PubMedView ArticleGoogle Scholar
- Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, Fortini C, Cofano EB, Triulzi C, Cafaro A: The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Vaccine 2008,26(5):727-737. 10.1016/j.vaccine.2007.11.040PubMedView ArticleGoogle Scholar
- Ferrantelli F, Maggiorella MT, Schiavoni I, Sernicola L, Olivieri E, Farcomeni S, Pavone-Cossut MR, Moretti S, Belli R, Collacchi B: A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. Vaccine 2011,29(16):2918-2932. 10.1016/j.vaccine.2011.02.006PubMedView ArticleGoogle Scholar
- Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, Pollard RB, Yee HF, Martin JN, Deeks SG, Shacklett BL: Immunodominant HIV-Specific CD8+ T-Cell Responses Are Common to Blood and Gastrointestinal Mucosa, and Gag-Specific Responses Dominate in Rectal Mucosa of HIV Controllers. J Virol 2010,84(19):10354-10365. 10.1128/JVI.00803-10PubMedPubMed CentralView ArticleGoogle Scholar
- Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I, Lindqvist M, Pereyra F, Walker BD, Heckerman D: HIV-Specific CD4 T Cell Responses to Different Viral Proteins Have Discordant Associations with Viral Load and Clinical Outcome. J Virol 2011,86(1):277-283.PubMedView ArticleGoogle Scholar
- Toapanta FR, DeAlmeida DR, Dunn MD, Ross TM: C3d adjuvant activity is reduced by altering residues involved in the electronegative binding of C3d to CR2. Immunol Lett 2010,129(1):32-38. 10.1016/j.imlet.2009.12.022PubMedPubMed CentralView ArticleGoogle Scholar
- Bower JF, Ross TM: A Minimum CR2 Binding Domain of C3d Enhances Immunity Following Vaccination. In Current Topics in Complement vol. 586. Edited by: Lambris JD. US: Springer; 2006:249-264.View ArticleGoogle Scholar
- Young KR, Smith JM, Ross TM: Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle. Virology 2004,327(2):262-272. 10.1016/j.virol.2004.07.009PubMedView ArticleGoogle Scholar
- Steckbeck JD, Orlov I, Chow A, Grieser H, Miller K, Bruno J, Robinson JE, Montelaro RC, Cole KS: Kinetic Rates of Antibody Binding Correlate with Neutralization Sensitivity of Variant Simian Immunodeficiency Virus Strains. J Virol 2005,79(19):12311-12320. 10.1128/JVI.79.19.12311-12320.2005PubMedPubMed CentralView ArticleGoogle Scholar
- Subbarao S, Otten RA, Ramos A, Kim C, Jackson E, Monsour M, Adams DR, Bashirian S, Johnson J, Soriano V: Chemoprophylaxis with Tenofovir Disoproxil Fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006,194(7):904-911. 10.1086/507306PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.